BIOMAT Database Logo BIOMAT Database Logo

Discovery of 4,6- and 5,7-Disubstituted Isoquinoline Derivatives as a Novel Class of Protein Kinase C ζ Inhibitors with Fragment-Merging Strategy. 2020

Masakazu Atobe, and Takayuki Serizawa, and Natsumi Yamakawa, and Kenichiro Takaba, and Yukiko Nagano, and Toshiaki Yamaura, and Eiichi Tanaka, and Atsutoshi Tazumi, and Shino Bito, and Masashi Ishiguro, and Masashi Kawanishi
Laboratory for Medicinal Chemistry, Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni, Shizuoka 410-2321, Japan.

Two chemical series of novel protein kinase C ζ (PKCζ) inhibitors, 4,6-disubstituted and 5,7-disubstituted isoquinolines, were rapidly identified using our fragment merging strategy. This methodology involves biochemical screening of a high concentration of a monosubstituted isoquinoline fragment library, then merging hit isoquinoline fragments into a single compound. Our strategy can be applied to the discovery of other challenging kinase inhibitors without protein-ligand structural information. Furthermore, our optimization effort identified the highly potent and orally available 5,7-isoquinoline 37 from the second chemical series. Compound 37 showed good efficacy in a mouse collagen-induced arthritis model. The in vivo studies suggest that PKCζ inhibition is a novel target for rheumatoid arthritis (RA) and that 5,7-disubstituted isoquinoline 37 has the potential to elucidate the biological consequences of PKCζ inhibition, specifically in terms of therapeutic intervention for RA.

UI MeSH Term Description Entries
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D011493 Protein Kinase C An serine-threonine protein kinase that requires the presence of physiological concentrations of CALCIUM and membrane PHOSPHOLIPIDS. The additional presence of DIACYLGLYCEROLS markedly increases its sensitivity to both calcium and phospholipids. The sensitivity of the enzyme can also be increased by PHORBOL ESTERS and it is believed that protein kinase C is the receptor protein of tumor-promoting phorbol esters. Calcium Phospholipid-Dependent Protein Kinase,Calcium-Activated Phospholipid-Dependent Kinase,PKC Serine-Threonine Kinase,Phospholipid-Sensitive Calcium-Dependent Protein Kinase,Protein Kinase M,Calcium Activated Phospholipid Dependent Kinase,Calcium Phospholipid Dependent Protein Kinase,PKC Serine Threonine Kinase,Phospholipid Sensitive Calcium Dependent Protein Kinase,Phospholipid-Dependent Kinase, Calcium-Activated,Serine-Threonine Kinase, PKC
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014018 Tissue Distribution Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios. Distribution, Tissue,Distributions, Tissue,Tissue Distributions
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein

Related Publications

Masakazu Atobe, and Takayuki Serizawa, and Natsumi Yamakawa, and Kenichiro Takaba, and Yukiko Nagano, and Toshiaki Yamaura, and Eiichi Tanaka, and Atsutoshi Tazumi, and Shino Bito, and Masashi Ishiguro, and Masashi Kawanishi
Discovery of 4,6-Disubstituted Pyrimidine Derivatives as Novel Dual VEGFR2/FGFR1 Inhibitors.
May 2021, Chemistry & biodiversity,
Masakazu Atobe, and Takayuki Serizawa, and Natsumi Yamakawa, and Kenichiro Takaba, and Yukiko Nagano, and Toshiaki Yamaura, and Eiichi Tanaka, and Atsutoshi Tazumi, and Shino Bito, and Masashi Ishiguro, and Masashi Kawanishi
Discovery of novel 2,6-disubstituted pyridazinone derivatives as acetylcholinesterase inhibitors.
May 2013, European journal of medicinal chemistry,
Masakazu Atobe, and Takayuki Serizawa, and Natsumi Yamakawa, and Kenichiro Takaba, and Yukiko Nagano, and Toshiaki Yamaura, and Eiichi Tanaka, and Atsutoshi Tazumi, and Shino Bito, and Masashi Ishiguro, and Masashi Kawanishi
Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy.
October 2021, Bioorganic & medicinal chemistry letters,
Masakazu Atobe, and Takayuki Serizawa, and Natsumi Yamakawa, and Kenichiro Takaba, and Yukiko Nagano, and Toshiaki Yamaura, and Eiichi Tanaka, and Atsutoshi Tazumi, and Shino Bito, and Masashi Ishiguro, and Masashi Kawanishi
Discovery of novel 2,4-disubstituted pyrimidines as Aurora kinase inhibitors.
February 2020, Bioorganic & medicinal chemistry letters,
Masakazu Atobe, and Takayuki Serizawa, and Natsumi Yamakawa, and Kenichiro Takaba, and Yukiko Nagano, and Toshiaki Yamaura, and Eiichi Tanaka, and Atsutoshi Tazumi, and Shino Bito, and Masashi Ishiguro, and Masashi Kawanishi
Discovery and evaluation of 3,5-disubstituted indole derivatives as Pim kinase inhibitors.
August 2018, Bioorganic & medicinal chemistry letters,
Masakazu Atobe, and Takayuki Serizawa, and Natsumi Yamakawa, and Kenichiro Takaba, and Yukiko Nagano, and Toshiaki Yamaura, and Eiichi Tanaka, and Atsutoshi Tazumi, and Shino Bito, and Masashi Ishiguro, and Masashi Kawanishi
Synthesis and antitumor activity evaluation of 4,6-disubstituted quinazoline derivatives as novel PI3K inhibitors.
September 2016, Bioorganic & medicinal chemistry letters,
Masakazu Atobe, and Takayuki Serizawa, and Natsumi Yamakawa, and Kenichiro Takaba, and Yukiko Nagano, and Toshiaki Yamaura, and Eiichi Tanaka, and Atsutoshi Tazumi, and Shino Bito, and Masashi Ishiguro, and Masashi Kawanishi
Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors.
February 2014, Bioorganic & medicinal chemistry,
Masakazu Atobe, and Takayuki Serizawa, and Natsumi Yamakawa, and Kenichiro Takaba, and Yukiko Nagano, and Toshiaki Yamaura, and Eiichi Tanaka, and Atsutoshi Tazumi, and Shino Bito, and Masashi Ishiguro, and Masashi Kawanishi
Discovery of 1,3-Disubstituted 2,5-Diketopiperazine Derivatives as Potent Class I HDACs Inhibitors.
January 2020, Chemical & pharmaceutical bulletin,
Masakazu Atobe, and Takayuki Serizawa, and Natsumi Yamakawa, and Kenichiro Takaba, and Yukiko Nagano, and Toshiaki Yamaura, and Eiichi Tanaka, and Atsutoshi Tazumi, and Shino Bito, and Masashi Ishiguro, and Masashi Kawanishi
Discovery of Sibiriline derivatives as novel receptor-interacting protein kinase 1 inhibitors.
March 2023, European journal of medicinal chemistry,
Masakazu Atobe, and Takayuki Serizawa, and Natsumi Yamakawa, and Kenichiro Takaba, and Yukiko Nagano, and Toshiaki Yamaura, and Eiichi Tanaka, and Atsutoshi Tazumi, and Shino Bito, and Masashi Ishiguro, and Masashi Kawanishi
Discovery of 1,8-disubstituted-[1,2,3]triazolo[4,5-c]quinoline derivatives as a new class of Hippo signaling pathway inhibitors.
September 2019, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!